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BACKGROUND/AIMS
Escherichia coli (E. coli) is responsible for the vast majority of uncomplicated bacterial urinary tract infection (UTI) cases in women. The high 
ability of the isolates to develop antimicrobial resistance makes the treatment difficult. In this study, we investigated the presence of plas-
mid-mediated quinolone resistance (PMQR) genes in E. coli isolates and their relationship with extended-spectrum beta-lactamases (ESBL).
MATERIAL and METHODS
A total of 300 E. coli isolates from urine specimens of women, including 108 ESBL producers and 192 non-ESBL producers, were analyzed. 
The ESBL production was examined using the E-test ESBL strips, and the carbapenemase activity was examined using the CarbaNP test. 
The presence of PMQR genes (qnrA, qnrB, qnrS, and aac (6´)-Ib) among urine isolates was investigated using polymerase chain reaction. 
Conjugation experiments were performed to detect the horizontal transferability of the PMQR-positive plasmid.
RESULTS
Among the ESBL-EC isolates, ciprofloxacin resistance was determined at 69%. Eight isolates were resistant to carbapenems. The aac(6’)-
Ib-cr variant was found in 40% of ciprofloxacin-resistant E. coli isolates. None of the isolates harbored the qnrA, qnrB, or qnrS gene. The 
transferability was 14% for aac(6’)-Ib-cr. The MICs of transconjugants showed increased resistance to fluoroquinolones compared with 
the recipient E. coli J53AzR.
CONCLUSION: This study showed that the frequency of PMQR genes in ESBL-producing superbug E. coli isolates reduced therapeutic 
options for treating community-acquired UTIs in affected women and that a careful use of antibiotics is very important.
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INTRODUCTION
All over the world, in outpatient practice, uncomplicated bacterial urinary tract infections (UTIs) are one of the most 
common community-acquired diseases. Escherichia coli (E. coli) is responsible for the vast majority of UTIs, and especially 
women suffer from UTIs because of the proximity of the urethra to the vagina and the rectum, changes in genital micro-
flora, hormonal influences, and other anatomical and physiological characteristics (1). E. coli is a part of the normal flora 
in the intestinal tract of a healthy human. Uropathogenic E. coli  is generally acquired from sexual partners, household 
members, pets, food, toilet, and during travel. However, the high ability of the isolates to develop antimicrobial resis-
tance makes the treatment difficult. These bacteria can transfer the resistance genes to other E. coli isolates and differ-
ent Gram-negative bacteria. Therefore, multidrug-resistant E. coli deserves a superbug label. Furthermore, antimicrobial 
options in treatment are limited due to multidrug resistance (2). Quinolones are the first choice for the treatment of UTIs 
caused by extended-spectrum-beta-lactamase (ESBL)-producing E. coli. However, the widespread use of quinolones for 
therapeutic and non-therapeutic purposes has led to the rapid spread of quinolone-resistant E. coli isolates worldwide 
(3). The resistance to quinolones usually occurs as a result of “DNA target mutations, overexpression of efflux pumps, 
loss of porins and mobile genetic elements encoded on plasmids, known as plasmid-mediated quinolone resistance 
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(PMQR) genes, namely  qnr,  aac (6’)-Ib-cr, and  qepA” (4, 5).  A 
series of PMQR determinants within the last 10 years further 
reveal a new issue about the resistance to quinolones. PMQR 
genes play an essential role in the development of low-level 
quinolone resistance and facilitate the emergence of high-lev-
el resistance in the presence of quinolones at treatment levels 
(6). PMQR genes, qnr (qnrA, qnrB, and qnrS), which protects the 
DNA gyrase and Type IV topoisomerase enzymes from quino-
lone inhibition, and  aac(6’)-Ib-cr,  which acetylates quinolones, 
and efflux by QepA and OqxAB have been reported in clinical 
isolates of Enterobacteriaceae, including E. coli (3, 6-8). In many 
studies, PMQR genes have frequently been shown to be asso-
ciated with genes encoding ESBL and aminoglycosides on the 
same plasmid (8, 9). Today, plasmids carrying qnr and ESBL de-
terminants represent a concern worldwide. Carbapenems are 
often the last-choice agents used for the treatment of patients 
with severe infections. However, carbapenemase-producing E. 
coli  has been increasingly reported, especially in clinical set-
tings (2, 10). Fosfomycin, known for over 40 years, has recently 
become attractive as an alternative agent for the treatment of 
UTIs (11). “The Infectious Diseases Society of America (IDSA) 
recommends that physicians obtain information on local resis-
tance rates, the appropriateness of empirical therapy proposals 
and that ongoing surveillance has been conducted to monitor 
changes in the susceptibility of uropathogens” (12, 13). This study 
aimed to investigate the presence of PMQR (qnrA, qnrB, qnrS, 
and aac(6’)-Ib-cr) genes, and also their relationship to ESBL 
among E. coli strains isolated from urine samples of outpatient 
Turkish women, with community-acquired UTI.
MATERIAL and METHODS
Methodology
A total of 300  E. coli  isolates were obtained from urine sam-
ples of outpatient Turkish women with symptoms suggestive 
of community-acquired UTIs in İstanbul University-Cerrahpaşa, 
Cerrahpaşa School of Medicine Hospital. In the study, the pa-
tients were aged 16-85 years. Patients who were pregnant, with 
functional, or structural anomalies of the urinary tract, and suf-
fering from an immunocompromized illness, and using immuno-
suppressants, and who were discharged from the hospital 10–15 
days before were excluded from the study. The identification 
and antimicrobial susceptibility were determined using the BD 
Phoenix automated identification and susceptibility testing sys-
tem (BD Diagnostic Systems, Sparks, MD). The isolates resistant 
or moderately susceptible to tested antibiotics were confirmed 
using the E-test (bioMerieux, France) method. The susceptibility 
of ciprofloxacin, carbapenems, tigecycline, colistin, and fosfomy-
cin was determined by E-test (bioMerieux, La Balme-les-Grottes, 
France) method according to manufacturer’s instructions. The 
results were interpreted according to the European Committee 
on Antimicrobial Susceptibility Testing (14). The ESBL produc-
tion was examined using the double-ended E-test ESBL strips 
(AB Biodisk, Solna, Sweden) containing gradients of cefotaxime 
(CT) or ceftazidime (TZ) or cefepime (FEP) at one end and ce-
fotaxime or ceftazidime or cefepime plus clavulanic acid (CTL, 
TZL, and FEL) at the other, according to the manufacturer’s 
instructions. The carbapenemase activity was investigated 
using the Carba NP test (RAPIDEC CARBA NP (bioMerieux, 
La Balmeles-grottes, France) (15). Quinolone-resistant isolates 
were screened for the presence of PMQR (qnrA,  qnrB,  qnrS, 
and aac(6’)-Ib) genes by the polymerase chain reaction (PCR). 
DNA was extracted from the fresh culture of E. coli colonies ac-
cording to the protocol performed using the GeneJET Genom-
ic DNA Purification kit (Thermo Scientific, USA). The determi-
nation of PMQR (qnrA,  qnrB,  qnrS, and  aac(6’)-Ib) genes was 
performed using PCR. All  aac (6’)-1b  positive amplicons were 
investigated by digestion with BseGI (Fermantas, USA) restric-
tion enzyme to determine the aac (6’)-1b-cr variant. The amplifi-
cation of qnrA, qnrB, qnrS, and aac(6’)-1b genes was performed 
using the primers presented in Table 1 (4, 9, 16-18).
Conjugation Assays Used to Detect PMQR Transferability 
Conjugation experiments were performed to detect whether 
the quinolone resistance could be transferred horizontally to 
a plasmid-free  E. coli  strain from  E. coli  urine isolates carrying 
PMQR-positive plasmids. A plasmid-free, sodium azide-resis-
tant  E. coli  J53 (AzR) was used as the recipient, as described 
previously (19). The recipient (J53) and donor urine isolates 
were inoculated into the Luria-Bertani (LB) broth (Difco) and 
grown overnight at 37°C. The equal volumes of the donor and 
recipient cultures were mixed and incubated overnight at 37°C. 
The serial dilutions were homogeneously spread onto trypti-
case soy agar (Oxoid) plates supplemented with sodium azide 
(150 µg/mL, Sigma-Aldrich) and ciprofloxacin (0.25 µg/mL, Sig-
ma-Aldrich). The transconjugants were selected and collected 
on the plates. PCR was performed to determine the presence 
of PMQR determinants (20). Plasmid DNAs of transconjugants 
and donor isolates were extracted using the GenElute Plasmid 
Miniprep Kit (Sigma-Aldrich, Vienna, Austria) according to the 
manufacturer’s instructions. The size of plasmid was estimated 
by electrophoresis using a 0.7 % (w/v) agarose gel, comparing 
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TABLE 1. Primers used for the detection of qnr and aac (6’)-Ib-cr genes 
     Predicting the size of 
Target gene   Primer sequence (5′→ 3′) Gene size Genebank accession No. amplicon (bp)
qnrA F TCAGCAAGAGGATTTCTCA 657 KC493127.1 627
 R GGCAGCACTATTACTCCCA   
qnrB F ATGACGCCATTACTGTATAA 681 EF634464.1 562
 R GATCGCAATGTGTGAAGTTC   
qnrS F ACGACATTCGTCAACTGCAA 656 EU391634.1 417
 R TAAATTGGCACCCTGTAGGC   
aac(6’)-1b-cr F TTGCGATGCTCTATGAGTGGCTA 519 Q214316.1 482
 R CTCGAATGCCTGGCGTGTTT   
the known plasmid molecular size markers of E. coli V517 harbor-
ing plasmids of 54.4, 7.1, 5.6, 5.2, 3.0, 2.7, and 2.1 kb, as previously 
described (19). MICs of ciprofloxacin were determined for the 
PMQR gene-positive donors, recipients, and transconjugants 
using the E-test.
Quality control was performed using standard strains of  E. 
coli  ATCC 25922, ATCC 35218,  Staphylococcus aureus  ATCC 
29213, and Pseudomonas aeruginosa ATCC 27853. 
Statistical Analysis
The statistical analysis of the data was carried out using Fish-
er’s exact test. A p-value of p<0.05 was accepted as statistically 
significant.
RESULTS 
A total of 300 E. coli isolates were obtained from urine samples 
of outpatient women with symptoms suggestive of a UTI. The 
ESBL production was detected in 36% (108/300) of isolates.
Antimicrobial Susceptibility Test
The antimicrobial resistance rates were significantly higher in 
ESBL-producing E. coli (ESBL-EC) isolates than in non-ESBL-EC 
isolates (p<0.05) (Figure 1). Thirty-five percent (105/300) were 
resistant to ciprofloxacin. Ciprofloxacin had MIC ranges of 0.008 
to ≥32 µg/mL with MIC50 at 0.5 µg/mL and MIC90 at 1 µg/mL. 
Among the ESBL-EC isolates, ciprofloxacin resistance was de-
termined at 69% (75/108). The ESBL production was significant-
ly more frequent among ciprofloxacin-resistant  E. coli  (CREC) 
isolates than among ciprofloxacin-susceptible isolates (33/108) 
(p<0.0001) (Figure 2). Sixty-five percent (68/105) of CREC iso-
lates belonged to women aged >40 years. Eight isolates were 
resistant to carbapenems, and the MICs of the isolates were 
determined ≥32 µg/mL for imipenem, meropenem, and ertap-
enem, and their carbapenemase activities were positive. These 
isolates were both resistant to ciprofloxacin and positive for 
ESBL production. One of the 8 isolates belonged to a 51-year-
old woman, and others belonged to young women (average 25 
years old).
ESBL-CREC isolates were highly resistant to ampicillin, cefurox-
ime, cefotaxime, ceftazidime (100%), amoxicillin/clavulanic acid, 
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FIGURE 1. Antimicrobial resistance rates of ESBL-EC and non-ESBL-
EC isolates
AMP: Ampicillin; AN: Amikacin; AMC: Amoxicillin/Clavulanic Acid; 
TZP: Piperacillin-Tazobactam; CXM: Cefuroxime; FEP: Cefepime; 
CTX: Cefotaxime; IMP: Imipenem; SXT: Trimethoprim-Sulfamethoxaz-
ole; F: Fosfomycin; NF: Nitrofurantoin; CAZ: Ceftazidime.
FIGURE 3. Antimicrobial resistance rates of E. coli isolates according to the presence or absence of ciprofloxacin resistance and ESBL production 
AMP: Ampicillin; AN: Amikacin; AMC: Amoxicillin/Clavulanic Acid; TZP: Piperacillin-Tazobactam; CXM: Cefuroxime; FEP: Cefepime; CTX: Cefo-
taxime; IMP: Imipenem; SXT: Trimethoprim-Sulfamethoxazole; F: Fosfomycin; NF: Nitrofurantoin; CAZ: Ceftazidime.
FIGURE 2. Percentage of ESBL production among CREC isolates
ESBL production was significantly more frequent among ciproflox-
acin-resistant E. coli isolates than among ciprofloxacin-susceptible 
isolates (33/108) (p<0.0001).
cefepime, and trimethoprim–sulfamethoxazole (73.3%). The re-
sistance was lower to amikacin (20%) and nitrofurantoin (6.6%) 
(Figure 3). The combined resistance to third-generation cepha-
losporins, carbapenems, ciprofloxacin, amikacin, trimethoprim–
sulfamethoxazole, and nitrofurantoin was detected in 2.6% 
(8/300) of urine isolates. Fosfomycin, tigecycline, and colistin 
resistance was not detected in any of the isolates.
Prevalence of PMQR Genes
Forty percent (42/105) of CREC isolates were positive for aac(6’)-
Ib-cr  variant, of which 50% (21/42) were ESBL producers, and 
28% (6/21) of these isolates were also resistant to carbapen-
ems. None of the isolates harbored qnrA, qnrB, and qnrS genes.
Conjugation Experiments 
Transconjugants (with plasmid sizes 54-100 kb) were success-
fully obtained from 6 of 42 aac(6’)-Ib-cr gene-positive E. coli iso-
lates used as donors. The  aac(6’)-Ib-cr  gene was successfully 
transferred from 6  aac(6’)-Ib-cr  gene-positive E. coli urine iso-
lates to their transconjugants. Transferability was 14% (6/42) 
for aac(6’)-Ib-cr. E. coli isolates that harbored aac(6’)-Ib-cr were 
resistant to ciprofloxacin (MICs 32-256 µg/mL). The MICs of ci-
profloxacin for the 6 transconjugants ranged from 0.25 to 1 µg/
mL, or were 31- to 125-fold higher than that for the recipient E. 
coli J53AzR (MIC 0.008µg/mL). 
The PCR amplification products of  aac(6’)-Ib-cr gene in CREC 
isolates are shown in Figure 4.
DISCUSSION 
UTIs are the most common infections in women, and over 50% 
of women experience UTI at least once in their lifetime. UTI can 
significantly affect the quality of life. E. coli is the most common 
causative agent in the UTIs of women. These bacteria can eas-
ily become resistant. Many reports have shown that the preva-
lence of multidrug-resistant E. coli  isolates is increasing world-
wide because of the dissemination of mobile genetic elements 
(21-24). A surveillance study conducted in Europe between 2004 
and 2010, including Turkey, reported that the ESBL production is 
positive in the mean 15% of E. coli  isolates from different sam-
ples, and Turkey has the highest percentage with 25% (23). In the 
present study, the ESBL production was 36% among the urine 
isolates of E. coli from outpatient women patients.
An increase in quinolone resistance among ESBL-EC isolates 
has been reported all over the world. In an antimicrobial resis-
tance surveillance study report on ECDC in 2012, the average 
percentage of resistance to quinolone was 22%, and it was 
predominant in Italy and Cyprus (42%), and Slovakia (41%) (21), 
and in Turkey (52%) (22). In a study conducted in our hospital 
in 2009, the rate of ciprofloxacin resistance among ESBL-EC 
blood isolates was 57.6% (24). In the present study, ciprofloxacin 
resistance was determined as 69% (75/108) in ESBL-EC urine 
isolates. The ESBL production was significantly more frequent 
among our CREC isolates than among ciprofloxacin-susceptible 
isolates (p<0.0001). 
PMQR genes may facilitate the spreading and increase the 
prevalence of quinolone-resistant isolates. The aac(6’)-Ib-cr en-
codes a bifunctional aminoglycoside 6’-N-acetyltransferase 
capable of acetylating both aminoglycosides and fluoroquino-
lones (25). In the many studies conducted on E. coli  in different 
countries,  the frequency rates of  the qnr  gene were reported 
at rates 11%-75% (26-28). In studies conducted in Turkey, the 
most prevalent PMQR determinant was  aac(6’)-Ib-cr  (at rates 
46%–60%) (29-31). In the present study, we observed that the 
frequency of aac(6’)-Ib-cr was 40% (42/105) in CREC isolates. 
Several studies demonstrated the association between aac(6’)-
Ib-cr  and the ESBL (31-33). Similarly, we determined that 50% 
of E. coli  isolates harboring aac(6’)-Ib-cr were ESBL producers. 
The conjugation experiments demonstrated that  aac(6’)-Ib-
cr  was transferable. The MICs of ciprofloxacin for transconju-
gants harboring  aac(6’)-Ib-cr  were 31- to 125- fold higher than 
the MIC for the recipient  E. coli  J53AzR. In conjugation exper-
iments, we showed the possibility that the  aac(6’)-Ib-cr  gene 
could be transferred horizontally among isolates of E. coli, caus-
ing uncomplicated community-acquired UTI in Turkish women.
Several reports of  E. coli  resistant to aminoglycosides are in-
creasing worldwide (21, 22, 24). The resistance to amikacin was 
reported as 11% for ESBL-EC in the United States (34). In the 
EARSS Annual Report, the resistance to aminoglycosides in  E.
coli  isolated from different samples was 35% in Turkey (22). In 
the current study, amikacin resistance was detected at 20% in 
urine isolates.
Carbapenems are also considered among the last-resort an-
tibiotics in the treatment of serious infections caused by multi-
drug-resistant members of the Enterobacteriaceae, including E. 
coli. However, because of the global increase of carbapenem 
resistance, these bacteria have become a worldwide problem 
(21). In the present study, 8 isolates were resistant to carbapen-
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FIGURE 4. PCR amplification products of the aac(6’)-Ib-cr gene in CREC isolates
ems (MICs>32 µg/mL). These isolates were both resistant to ci-
profloxacin, and ESBL was positive.
The percentage of combined resistance to third-generation 
cephalosporins, fluoroquinolones, and aminoglycosides was 4% 
in Europe (21). In the current study, the percentage of combined 
resistance, including carbapenems and nitrofurantoin among 
the ESBL-EC isolates in urine samples of women with symptoms 
suggestive of a community-acquired UTIs was 2.6%.
Tigecycline was approved by the Food and Drug Administration 
(FDA) in 2005, and it, like “old” antibiotics, phosphomycin and 
colistin, is among the remaining options in clinical use for the 
treatment of UTIs caused by multidrug-resistant E. coli  isolates 
(35). In the last decade, colistin has been increased for the treat-
ment of multidrug-resistant Gram-negative bacilli, especially in 
combination with other drugs (35).
In the 2013 report by IDSA, ESBL-EC was listed among the 6 
drug-resistant microbes urgently needed in new treatments 
(36). These data led to reconsidering nontraditional antibiotics 
such as fosfomycin, a phosphonic acid derivative approved by 
the FDA for the treatment of uncomplicated UTIs in women. Re-
cent reports have shown that it has in vitro activity against mul-
tidrug-resistant pathogens, including ESBL-CREC (37, 38). As it 
was also seen in the present study, fosfomycin has shown good 
in vitro activity against ESBL-CREC isolates. It may be a prom-
ising treatment option. However, clinical data regarding the use 
of fosfomycin in the treatment of UTIs caused by multidrug-re-
sistant pathogens are still limited, and concerns about the 
widespread use of fosfomycin include tolerability, cost, and re-
sistance (39). A recent analysis reports a fosfomycin resistance 
rate of 0.5% in community-acquired E. coli UTI in women in the 
United Kingdom (11). A systematic review of data, mainly from 
Europe and Asia, showed that 97% of ESBL-EC was susceptible 
to fosfomycin. Data from both in vitro and clinical studies are 
suggesting that fosfomycin should be used with caution in in-
fections caused by ESBL-EC. In these studies, it is emphasized 
that the reason for the emergence of resistance to fosfomycin in 
ESBL-EC may be related to the increased use of this agent (37).
The ability of E. coli to transfer resistance genes to other bacte-
ria causes the spread of antimicrobial resistance. This situation 
threatens the effectiveness of existing antibiotics. High rates of 
recurrent UTIs suggest that antibiotics are not an effective ther-
apy for all UTIs, and UTIs are resulting in billions of dollars in 
health care costs annually.
In conclusion, our findings indicate that the rates of ciproflox-
acin resistance among urine isolates of  E. coli  in women are 
high, that CREC isolates carry a transferable aac(6’)-Ib-cr gene, 
and that they have a combined drug resistance (2.6%), includ-
ing carbapenems of ESBL-EC urine isolates. These data point 
out that the multidrug resistance has the potential to spread 
among E. coli isolates from urine samples of outpatient women 
with community-acquired UTIs. We observed it had a low re-
sistance for nitrofurantoin (6.6%). None of our multidrug-resis-
tant E. coli urine isolates showed resistance to fosfomycin, tige-
cycline, or colistin. There is a need for accurate epidemiological 
data for appropriate empirical treatment in patients with both 
the community and the hospital hospital-acquired infections in 
each country. Therefore, it is crucial to apply antimicrobial re-
sistance prevention and control strategies to reduce morbidity, 
mortality, and health care costs; limit the potential spread of re-
sistance genes; and ensure careful antibiotic use in UTIs caused 
by E. coli with superbug potency.  
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